摘要
目的观察通心络胶囊治疗急性冠脉综合征患者血清可溶性CD40L(sCD40L)的变化,了解其对斑块稳定和免疫炎症抑制的影响。方法50例急性冠脉综合征患者,随机分为通心络治疗组(n=33)和他汀类治疗组(n=17),测定治疗前后血清sCD40L水平的变化。结果两组患者血清治疗前后sCD40L水平明显下降,通心络组下降34.6%,他汀类组下降33.4%,与治疗前比较均有统计学差异(P<0.01);而两组用药前比较和用药后比较均无统计学差异(P>0.05)。结论急性冠脉综合征患者早期予以通心络胶囊治疗一疗程,可明显降低sCD40L的水平,有利于动脉粥样硬化斑块的稳定。
ObjectiveTo measure serum soluble CD40L(sCD40L)in patients with acute coronary syndromes on Tong-xin-luo therapy, compare with patients on statin therapy, and to evaluate the effect of Tong-xin-luo on stabilization of atherosclerotic plaque and inhibition of immune-inflammation.MethodsFifty patients with acute coronary syndromes were enrolled in this study and randomized into two groups; 33 subjects with Tong-xin-luo 6 capsules daily and 17 subjects with statin 40 mg daily. Serum sCD40L was measured before treatment and 30 d later.Results(After treatment,) serum sCD40L decreased significantly(P<0.01) both in Tong-xin-luo group and statin group by 34.6% and 33.4%, respectively. There was no significant difference in serum sCD40L change between the two groups (P>0.05).ConclusionEarly Tong-xin-luo therapy in patients with acute coronary syndromes signifi-(cantly) lowers the serum inflammatory factor and favors stabilization of the atherosclerotic plaque.
出处
《上海第二医科大学学报》
CSCD
北大核心
2005年第7期727-729,共3页
Acta Universitatis Medicinalis Secondae Shanghai
